Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

LIPO

Lipella Pharmaceuticals Inc

Jul 26 • 04:00PM ET

0.4041

Dollar change +0.0091
Percentage change 2.30	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.78	Insider Own	36.79%	Shs Outstand	6.05M	Perf Week	-11.59%
Market Cap	3.08M	Forward P/E	-	EPS next Y	-0.28	Insider Trans	2.38%	Shs Float	4.81M	Perf Month	-14.20%
Income	-4.74M	PEG	-	EPS next Q	-0.13	Inst Own	4.99%	Short Float	0.07%	Perf Quarter	-42.96%
Sales	0.48M	P/S	6.41	EPS this Y	50.65%	Inst Trans	-	Short Ratio	0.07	Perf Half Y	-60.38%
Book/sh	0.36	P/B	1.11	EPS next Y	26.32%	ROA	-122.37%	Short Interest	0.00M	Perf Year	-79.84%
Cash/sh	0.28	P/C	1.46	EPS next 5Y	-	ROE	-148.74%	52W Range	0.36 - 2.71	Perf YTD	-60.38%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-189.86%	ROI	-183.46%	52W High	-85.09%	Beta	0.59
Dividend TTM	-	Quick Ratio	5.46	Sales past 5Y	20.14%	Gross Margin	-	52W Low	11.91%	ATR (14)	0.05
Dividend Ex-Date	-	Current Ratio	5.46	EPS Y/Y TTM	-52.07%	Oper. Margin	-1021.92%	RSI (14)	33.04	Volatility	12.53% 10.76%
Employees	7	Debt/Eq	0.05	Sales Y/Y TTM	77.45%	Profit Margin	-993.39%	Recom	1.00	Target Price	2.00
Option/Short	No / Yes	LT Debt/Eq	0.01	EPS Q/Q	12.10%	Payout	-	Rel Volume	1.14	Prev Close	0.40
Sales Surprise	0.00%	EPS Surprise	0.00%	Sales Q/Q	23.58%	Earnings	May 29	Avg Volume	44.99K	Price	0.40
SMA20	-10.88%	SMA50	-29.71%	SMA200	-53.70%	Trades		Volume	51,214	Change	2.30%

May-31-24 08:00AM	Lipella Pharmaceuticals Announces Completion of Site Initiation Visit for Phase 2a Trial of LP-310 in Oral Lichen Planus (GlobeNewswire)
May-29-24 12:53PM	LIPO Stock Earnings: Lipella Pharmaceuticals Reported Results for Q1 2024 (InvestorPlace)
08:00AM	Lipella Pharmaceuticals Announces Abstract Publication at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
May-24-24 01:53PM	LIPO Stock Earnings: Lipella Pharmaceuticals Reported Results for Q4 2023 (InvestorPlace)
May-21-24 08:00AM	Following Guidance from U.S. Food & Drug Administration in Type-C Meeting Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2b (GlobeNewswire)
08:00AM	Loading…
Apr-17-24 08:00AM	Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise (GlobeNewswire)
Apr-05-24 08:00AM	Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024 (GlobeNewswire)
Apr-03-24 08:00AM	Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis (GlobeNewswire)
Mar-07-24 03:23PM	PRISM MarketView Spotlights Lipella Pharmaceuticals as it Seizes Opportunities in Rare Disease (GlobeNewswire)
Mar-05-24 08:00AM	Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical Pipeline (GlobeNewswire) -21.57%
Feb-20-24 08:00AM	Lipella Pharmaceuticals to Present at PropThink Digital Investor Conference (GlobeNewswire)
Dec-20-23 08:00AM	Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones Accomplished (GlobeNewswire)
Nov-12-23 08:20PM	Lipella Pharmaceuticals gets ODD for LP-310 to treat GvHD (Pharmaceutical Business Review)
Nov-10-23 08:00AM	FDA Grants Orphan Designation for Lipella's LP-310 Drug Candidate for Oral Graft-versus-Host Disease (PR Newswire) -8.12%
Oct-25-23 04:05PM	Lipella Pharmaceuticals Announces Closing of $2 Million Private Placement Priced At-The-Market Under Nasdaq Rules (PR Newswire) -24.89% -31.95%
08:00AM	Loading…
Oct-24-23 08:00AM	Lipella Pharmaceuticals Announces $2 Million Private Placement Priced At-The-Market Under Nasdaq Rules (PR Newswire)
Oct-23-23 08:45AM	Rising Number of Studies to Develop Novel Therapies For Pancreatic Ductal Adenocarcinoma (PDAC) Intensely Increasing (PR Newswire)
08:30AM	Lipella Pharmaceuticals to Present at the Fall Foliage MicroCap Rodeo Conference (ACCESSWIRE)
Oct-20-23 08:00AM	Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-310 for Oral Lichen Planus (PR Newswire) +29.81%
Sep-21-23 08:30AM	Lipella Pharmaceuticals' Phase 2a Clinical Study Results Published in the Journal of Urology and Nephrology (PR Newswire)
Jun-13-23 08:30AM	Lipella Pharmaceuticals: Addressing Significant Unmet Need for Cancer Survivors, Delivering Long Term Value for Shareholders (NewMediaWire) +6.75%
May-15-23 09:15AM	Lipella Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Update (PR Newswire)
May-14-23 08:12AM	Lipella Pharmaceuticals First Quarter 2023 Earnings: US$0.19 loss per share (vs US$0.19 loss in 1Q 2022) (Simply Wall St.)
May-01-23 08:30AM	Lipella Pharmaceuticals Delivers Late-Breaking Presentation at the American Urological Association Annual Meeting (PR Newswire) -20.90%
Apr-17-23 08:30AM	Lipella Pharmaceuticals Enters Manufacturing Collaboration Agreement with Cook MyoSite (PR Newswire)
Apr-05-23 08:30AM	Lipella Pharmaceuticals Doses First Patient in Human Study of Innovative Contrast Agent (PR Newswire)
Mar-31-23 08:00AM	Lipella Provides Business Update and Reports 2022 Financial Results (PR Newswire) +5.98%
Mar-16-23 08:30AM	Lipella Pharmaceuticals Successfully Completes Phase 2a Clinical Trial; Announces Late-Breaking Presentation at the Annual Meeting of the American Urological Association (PR Newswire) +36.07%
Mar-01-23 08:00AM	Lipella Pharmaceuticals Announces Creation of Oral Health Scientific Advisory Board (PR Newswire)
Jan-11-23 07:30AM	Lipella Pharmaceuticals Announces Successful Top Line Results of Phase 2A Clinical Trial of LP-10 (PR Newswire) +18.01%
08:00AM	Loading…
Jan-09-23 08:00AM	Lipella Pharmaceuticals to Present at January 2023 Biotech Showcase in San Francisco (PR Newswire)
Dec-22-22 04:05PM	Lipella Announces Closing of Initial Public Offering for Gross Proceeds of $7 Million (PR Newswire) +12.78% -10.89%

Lipella Pharmaceuticals, Inc. develops and commercializes lipid-based therapies for common bladder syndromes. It offers LP-08 which consists of Sphingomyelin Phospholipid bilayers separated by aqueous compartments, LP-09, a liposomal formulation of Botulinum toxin, and LP-10, a proprietary liposomal formulation of Tacrolimus, a potent immunosuppressant and anti-inflammatory agent. The company was founded by Jonathan Kaufman and Michael Chancellor on February 15, 2005 and is headquartered in Pittsburgh, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kaufman Jonathan H	See remarks below.	May 14 '24	Buy	0.76	10,000	7,590	898,849	May 15 04:39 PM
Kaufman Jonathan H	See remarks below.	Mar 19 '24	Buy	0.87	25,000	21,802	888,849	Mar 19 06:21 PM
Kaufman Jonathan H	See remarks below.	Mar 18 '24	Buy	0.79	30,000	23,649	863,849	Mar 19 06:21 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LIPO

Lipella Pharmaceuticals Inc

Upgrade your FINVIZ experience